Current Rheumatology Reports

, Volume 13, Issue 1, pp 51–58

Imatinib and the Treatment of Fibrosis: Recent Trials and Tribulations



Imatinib mesylate has become a therapy of interest for the treatment of systemic sclerosis because of its ability to inhibit c-Abl and platelet-derived growth factor receptor, tyrosine kinases involved in profibrotic pathways. Preclinical data using in vitro and murine models of fibrosis have demonstrated the antifibrotic properties of imatinib. Imatinib is currently used widely in the treatment of chronic myelogenous leukemia, gastrointestinal stromal tumors, and other conditions, and a large amount of information is available regarding the safety of the medication in these patient populations. Whether imatinib will be tolerable or effective in the treatment of systemic sclerosis is the subject of several investigations. The aim of this review is to summarize this body of research to date.


Imatinib Systemic sclerosis Scleroderma Fibrosis Tyrosine kinase inhibitor 


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Varga J, Abraham D: Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007, 117:557–567.CrossRefPubMedGoogle Scholar
  2. 2.
    Tyndall AJ, Bannert B, Vonk M, et al.: Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010, 69:1809–1815.CrossRefPubMedGoogle Scholar
  3. 3.
    Quillinan NP, Denton CP: Disease-modifying treatment in systemic sclerosis: current status. Curr Opin Rheumatol 2009, 21:636–641.CrossRefPubMedGoogle Scholar
  4. 4.
    Nihtyanova SI, Tang EC, Coghlan JG, et al.: Improved survival in systemic sclerosis is associated with better ascertainment of internal organ disease: a retrospective cohort study. QJM 2010, 103:109–115.CrossRefPubMedGoogle Scholar
  5. 5.
    Clements PJ, Lachenbruch PA, Seibold JR, et al.: Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol 1993, 20:1892―1896.PubMedGoogle Scholar
  6. 6.
    Medsger TA: Natural history of systemic sclerosis and the assessment of disease activity, severity, functional status, and psychologic well-being. Rheum Dis Clin North Am 2003, 29:255–273.CrossRefPubMedGoogle Scholar
  7. 7.
    • Amjadi S, Maranian P, Furst DE, et al.: Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trials. Arthritis Rheum 2009, 60:2490–2498. In a pooled analysis of three randomized controlled trials, the authors demonstrated that SSc patients in clinical trials tend to demonstrate improvement in mRSS whether treated with placebo or drug. CrossRefPubMedGoogle Scholar
  8. 8.
    • Herrick AL, Lunt M, Whidby N, et al.: Observational study of treatment outcome in early diffuse cutaneous systemic sclerosis. J Rheumatol 2010, 37:116–124. Improvements in mRSS in patients with less than 3 years’ disease duration on a variety of different treatment regimens are described. CrossRefPubMedGoogle Scholar
  9. 9.
    • Varga JA, Trojanowska M: Fibrosis in systemic sclerosis. Rheum Dis Clin North Am 2008, 34:115–143. This is a comprehensive review of the pathophysiology of fibrosis in SSc. CrossRefPubMedGoogle Scholar
  10. 10.
    • Rosenbloom J, Castro SV, Jimenez SA: Narrative review: fibrotic diseases: cellular and molecular mechanisms and novel therapies. Ann Intern Med 2010, 152:159–166. This is a review of the molecular mechanisms of TGF-β and fibrosis. PubMedGoogle Scholar
  11. 11.
    Higley H, Persichitte K, Chu S, et al.: Immunocytochemical localization and serologic detection of transforming growth factor beta 1: association with type I procollagen and inflammatory cell markers in diffuse and limited systemic sclerosis, morphea, and Raynaud’s phenomenon. Arthritis Rheum 1994, 37:278–288.CrossRefPubMedGoogle Scholar
  12. 12.
    Ludwicka A, Ohba T, Trojanowska M, et al.: Elevated levels of platelet derived growth factor and transforming growth factor-beta 1 in bronchoalveolar lavage fluid from patients with scleroderma. J Rheumatol 1995, 22:1876–1883.PubMedGoogle Scholar
  13. 13.
    Klareskog L, Gustafsson R, Scheynius A, et al.: Increased expression of platelet-derived growth factor type B receptors in the skin of patients with systemic sclerosis. Arthritis Rheum 1990, 33:1534–1541.CrossRefPubMedGoogle Scholar
  14. 14.
    Baroni SS, Santillo M, Bevilacqua F, et al.: Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 2006, 354:2667–2676.CrossRefPubMedGoogle Scholar
  15. 15.
    Dragun D, Distler JH, Riemekasten G, Distler O: Stimulatory autoantibodies to platelet-derived growth factor receptors in systemic sclerosis: what functional autoimmunity could learn from receptor biology. Arthritis Rheum 2009, 60:907–911.CrossRefPubMedGoogle Scholar
  16. 16.
    Barst RJ: PDGF signaling in pulmonary arterial hypertension. J Clin Invest 2005, 115:2691–2694.CrossRefPubMedGoogle Scholar
  17. 17.
    Massague J, Seoane J, Wotton D: Smad transcription factors. Genes Dev 2005, 19:2783–2810.Google Scholar
  18. 18.
    • Bhattacharyya S, Ishida W, Wu M, et al.: A non-Smad mechanism of fibroblast activation by transforming growth factor-b via c-Abl and Egr-1: selective modulation by imatinib mesylate. Oncogene 2009, 28:1285–1297. These results position c-Abl downstream of TGF-β signaling and in turn position early growth response factor 1 downstream of this. Delineation of these pathways may demonstrate new areas for additional future therapeutic targets. CrossRefPubMedGoogle Scholar
  19. 19.
    Pannu J, Asano Y, Nakerakanti S, et al.: Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate. Arthritis Rheum 2008, 58:2528–2537.CrossRefPubMedGoogle Scholar
  20. 20.
    Jimenez SA, Gaidarova S, Saitta B, et al.: Role of protein kinase S-delta in the regulation of collagen gene expression in scleroderma fibroblasts. J Clin Invest 2001, 108:1395–1403.PubMedGoogle Scholar
  21. 21.
    Chen Y, Leask A, Abraham DJ, et al.: Heparan sulfate-dependent ERK activation contributes to the overexpression of fibrotic proteins and enhanced contraction by scleroderma fibroblasts. Arthritis Rheum 2008, 58:577–585.CrossRefPubMedGoogle Scholar
  22. 22.
    Distler JH, Jungel A, Huber LC, et al.: Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 2007, 56:311–322.CrossRefPubMedGoogle Scholar
  23. 23.
    • Akhmetshina A, Venalis P, Dees C, et al.: Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum 2009, 60:219–224. The authors used the Tsk1 murine and bleomycin-induced dermal fibrosis murine model to show that in models approximating established stages of fibrosis, imatinib inhibition of PDGF receptor and TGF-β signaling led to decreased dermal thickening. CrossRefPubMedGoogle Scholar
  24. 24.
    • Akhmetshina A, Dees C, Pileckyte M, et al.: Dual inhibition of c-Abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB J 2008, 22:2214–2222. TKIs dasatinib and nilotinib exhibited similar effects to what was seen with imatinib. CrossRefPubMedGoogle Scholar
  25. 25.
    Li M, Abdollahi A, Grone HJ, et al.: Late treatment with imatinib mesylate ameliorates radiation-induced lung fibrosis in a mouse model. Radiat Oncol 2009, 4:66.CrossRefPubMedGoogle Scholar
  26. 26.
    Yoshiji H, Noguchi R, Kuriyama S, et al.: Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats. Am J Physiol Gastrointest Liver Physiol 2005, 288:G907–G913.CrossRefPubMedGoogle Scholar
  27. 27.
    Wang S, Wilkes MC, Leof EB, et al.: Noncanonical TGF-beta pathways, mTORC1 and Abl, in renal interstitial fibrogenesis. Am J Physiol Renal Physiol 2010, 298:F142–F149.CrossRefPubMedGoogle Scholar
  28. 28.
    Maurer B, Stanczyk J, Jüngel A, et al.: MicroRNA-29, a key regulator of collagen expression in systemic sclerosis. Arthritis Rheum 2010, 62:1733–1743.CrossRefPubMedGoogle Scholar
  29. 29.
    • Kay J, High W: Imatinib mesylate treatment of nephrogenic systemic fibrosis. Arthritis Rheum 2008, 58:2543–2548. This case series of two patients with NSF treated with imatinib showed clinical and histologic improvement in the skin. CrossRefPubMedGoogle Scholar
  30. 30.
    • Olivieri A, Locatelli F, Zecco M, et al.: Imatinib for refractory chronic graft-versus-host disease with fibrotic features. Blood 2009, 114:709–718. In 19 patients with cGVHD, an overall response rate of 79% was seen with imatinib treatment, providing evidence for the efficacy of PDGF receptor inhibition in this fibrotic disease. CrossRefPubMedGoogle Scholar
  31. 31.
    Daniels CE, Wilkes MW, Edens M, et al.: Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin mediated lung fibrosis. J Clin Invest 2004, 114:1308–1316.PubMedGoogle Scholar
  32. 32.
    •• Daniels CE, Lasky JA, Limper AH, et al.: Imatinib treatment for IPF: randomized placebo controlled trial results. Am J Respir Crit Care Med 2010, 181:604–610. This was an investigator-initiated, multicenter, multinational, double-blind clinical trial in which 119 patients with IPF were randomly assigned to receive imatinib or placebo for 96 weeks. Treatment with imatinib did not improve survival or lung function. CrossRefPubMedGoogle Scholar
  33. 33.
    Cohen MH, Williams G, Johnson JR, et al.: Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 2002, 8:935–942.PubMedGoogle Scholar
  34. 34.
    Dagher R, Cohen M, Williams G, et al.: Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res 2002, 8:3034–3038.PubMedGoogle Scholar
  35. 35.
    Kerkelä R, Grazette L, Yacobi R, et al.: Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006, 12:908–916.CrossRefPubMedGoogle Scholar
  36. 36.
    Atallah E, Durand JB, Kantarjian H, et al.: Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood 2007, 110:1233–1237.CrossRefPubMedGoogle Scholar
  37. 37.
    Berman E, Nicolaides M, Maki RG, et al.: Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 2006, 354:2006–2013.CrossRefPubMedGoogle Scholar
  38. 38.
    Gordon JK, Magid SK, Maki RG, et al.: Elevations in creatine kinase in patients treated with imatinib mesylate (Gleevec). Leuk Res 2010, 34:827–829.CrossRefPubMedGoogle Scholar
  39. 39.
    Sfikakis PP, Gorgoulis VG, Katsiari CG, et al.: Imatinib for the treatment of refractory, diffuse systemic sclerosis. Rheumatology (Oxford) 2008, 47:735–737.CrossRefGoogle Scholar
  40. 40.
    van Daele PLA, Dik WA, Thio HB, et al.: Is imatinib mesylate a promising drug in systemic sclerosis? Arthritis Rheum 2008, 58:2549–2552.CrossRefPubMedGoogle Scholar
  41. 41.
    Distler JH, Manger B, Spriewald BM, et al.: Treatment of pulmonary fibrosis for twenty weeks with imatinib mesylate in a patient with mixed connective tissue disease. Arthritis Rheum 2008, 58:2538–2542.CrossRefPubMedGoogle Scholar
  42. 42.
    • Chung L, Fiorentino DF, Benbarak MJ, et al.: Molecular framework for response to imatinib mesylate in systemic sclerosis. Arthritis Rheum 2009, 60:584–591. This hypothesis-generating work posits the existence of an imatinib-responsive gene signature in certain dcSSc patients. CrossRefPubMedGoogle Scholar
  43. 43.
    Sabnani I, Zucker MJ, Rosenstein ED, et al.: A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide. Rheumatology 2009, 48:49–52.CrossRefPubMedGoogle Scholar
  44. 44.
    Hatano M, Yao A, Shiga T, et al.: Imatinib mesylate has the potential to exert its efficacy by down-regulating the plasma concentration of platelet-derived growth factor in patients with pulmonary arterial hypertension. Int Heart J 2010, 51:272–276.CrossRefPubMedGoogle Scholar
  45. 45.
    Spiera R, Gordon J, Mersten J, et al.: Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a one year, phase IIa, single arm, open label clinical trial [abstract]. Presented at the American College of Rheumatology Annual Scientific Meeting. Atlanta, GA; November 6–11, 2010.Google Scholar
  46. 46.
    Pope J, McBain DL, Petrlich L, et al.: A proof of concept trial of Gleevec (imatinib) in active diffuse scleroderma (DSSc) [abstract]. Presented at the American College of Rheumatology Annual Scientific Meeting. Philadelphia, PA; October 17–21, 2009.Google Scholar
  47. 47.
    Chung L, Ruiz P, Wood T, et al.: Evaluation of an imatinib response gene signature in patients with systemic sclerosis [abstract]. Presented at the American College of Rheumatology Annual Scientific Meeting. Atlanta, GA; November 6–11, 2010.Google Scholar
  48. 48.
    Saggar R, Khanna D, Mayes M, et al.: Open labeled study of imatinib mesylate (Gleevec) in the treatment of systemic sclerosis-associated active interstitial lung disease (SSc-ILD): preliminary results. Am J Respir Crit Care Med 2010, 181:A3991.Google Scholar
  49. 49.
    Distler O, Distler JHW, Varga J, et al.: A multi-center, open-label, proof of concept study of imatinib mesylate demonstrates no benefit for the treatment of fibrosis in patients with early, diffuse systemic sclerosis [abstract]. Presented at the American College of Rheumatology Annual Scientific Meeting. Atlanta, GA; November 6–11, 2010.Google Scholar
  50. 50.
    Denton CP, Nihtyanova SI, Varga J, et al.: Comparative analysis of change in modified Rodnan skin score in patients with diffuse systemic sclerosis receiving imatinib mesylate suggests similar disease course to matched patients receiving standard therapy [abstract]. Presented at the American College of Rheumatology Annual Scientific Meeting. Atlanta, GA; November 6–11, 2010.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Department of RheumatologyHospital for Special SurgeryNew YorkUSA

Personalised recommendations